This study is testing a new treatment for children and young adults (ages 1 to 24) with neuroblastoma or osteosarcoma that has come back or hasn't responded to other treatments. This treatment uses special immune cells called i15.NKG2D.zeta NK cells and C7R.GD2.CAR-T cells. These cells are designed to target a substance called GD2 found on the cancer cells. The main goal is to find the highest safe dose of these cells when given together. Researchers will also look at how long these cells stay in your body and what effect they have on your cancer. This is a gene transfer study, meaning new genes are added to your immune cells to help them fight the cancer.

Study design

This study plans to enroll 27 participants. It is designed to find the safest dose of the study treatments.

What's involved

You would have your blood taken to create the special T cells. You would receive an infusion of i15.NKG2D.zeta-NK cells, followed by C7R.GD2.CAR-T cells five days later. You will be monitored for about 3 hours after the NK cell infusion.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for a total of 15 years to monitor for any long-term side effects from the gene transfer.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.